Ensayo clínico aleatorizado de tres pautas de quimioprofilaxis para prevenir la tuberculosis en pacientes infectados por el VIH con anergia cutánea

Rivero, Antonio; López‐Cortés, Luis F.; Castillo, Rafael; Lozano, Fernando; García, Miguel Ángel; Díez, Felipe; Escribano, José Carlos; Canueto, Jesús; Pasquau, Juan; Hernández, Juan José; Polo, Rosa; Martínez‐Marcos, Francisco Javier; Kindelán, José María; Rey, Rafael Ubaldo Gosálvez; Infecciosas, Grupo Andaluz para el estudio de las Enfermedades

doi:10.1157/13048575

Cited by 12 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified 19 studies comparing primary IPT with no treatment that reported isoniazid resistance among adults ( 9 , 18 – 35 ). Of the 11 studies from the pre-HIV era, 4 ( 23 – 26 ) were excluded because resistance data from the control group were incomplete or not reported.…”

Section: Resultsmentioning

confidence: 99%

“…Study population size was 121–1,718. RCTs administered isoniazid for 6 months at 300 mg daily ( 30 , 31 , 34 , 35 ) or 900 mg twice weekly ( 33 ); in the cohort study, an unspecified dose was given for 9 to 12 months ( 32 ). …”

Section: Resultsmentioning

confidence: 99%

“…Three RCTs reported that the treatment was concealed: 2 used sealed envelopes ( 33 , 34 ), and 1 used numbered packages containing isoniazid or matching placebo ( 27 ). Eight RCTs were double-blinded ( 18 , 20 , 21 , 27 , 30 , 31 , 33 , 34 ), although in 1 study, isoniazid and placebo groups may have received different numbers of tablets ( 34 ); 2 were not blinded ( 19 , 35 ), and 2 did not report blinding ( 9 , 22 ). Loss to follow-up was reported in 11 studies: in 6, this loss was <20% in both groups (Tables 2, 3).…”

Section: Resultsmentioning

confidence: 99%

“…In the 7 studies that reported this information, 55%–100% of TB cases were sputum-culture positive ( 20 , 22 , 27 , 31 , 32 , 34 , 35 ). In 4 of these studies, >90% of culture-positive isolates underwent resistance testing ( 22 , 27 , 31 , 35 ). In total, 158 persons in the isoniazid groups and 328 in control groups had isolates tested for resistance to isoniazid.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Isoniazid Preventive Therapy and Risk for Resistant Tuberculosis

Balcells

Thomas

Godfrey‐Faussett

et al. 2006

Emerg. Infect. Dis.

206

135

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Isoniazid Preventive Therapy and Risk for Resistant Tuberculosis

Balcells

Thomas

Godfrey‐Faussett

et al. 2006

Emerg. Infect. Dis.

206

135

View full text Add to dashboard Cite

show abstract

“…The majority of clinical trials and prospective cohort studies have shown that treatment with isoniazid for six or 12 month periods prevents tuberculosis and is safe in people infected with HIV and with TST ≥ 5 mm [19-25]. Based on the existing evidence, LTBI treatment with daily doses of isoniazid for six or nine months is recommended in individuals living with HIV [26,27].…”

Section: Introductionmentioning

confidence: 99%

An evaluation of factors associated with taking and responding positive to the tuberculin skin test in individuals with HIV/AIDS

et al. 2011

View full text Add to dashboard Cite

BackgroundThe tuberculin skin test (TST) is still the standard test for detecting latent infection by M tuberculosis (LTBI). Given that the Brazilian Health Ministry recommends that the treatment of latent tuberculosis (LTBI) should be guided by the TST results, the present study sets out to describe the coverage of administering the TST in people living with HIV at two referral health centers in the city of Recife, where TST is offered to all patients. In addition, factors associated with the non-application of the test and with positive TST results were also analyzed.MethodsA cross-sectional study was carried out with HIV patients, aged 18 years or over, attending outpatient clinics at the Correia Picanço Hospital/SES/PE and the Oswaldo Cruz/UPE University Hospital, who had been recommended to take the TST, in the period between November 2007 and February 2010. Univariate and multivariate logistic regression analyses were carried out to establish associations between the dependent variable - taking the TST (yes/no), at a first stage analysis, and the independent variables, followed by a second stage analysis considering a positive TST as the dependent variable. The odds ratio was calculated as the measure of association and the confidence interval (CI) at 95% as the measure of accuracy of the estimate.ResultsOf the 2,290 patients recruited, 1087 (47.5%) took the TST. Of the 1,087 patients who took the tuberculin skin test, the prevalence of TST ≥ 5 mm was 21.6% among patients with CD4 ≥ 200 and 9.49% among those with CD4 < 200 (p = 0.002). The patients most likely not to take the test were: men, people aged under 39 years, people with low educational levels and crack users. The risk for not taking the TST was statiscally different for health service. Patients who presented better immunity (CD4 ≥ 200) were more than two and a half times more likely to test positive that those with higher levels of immunodeficiency (CD4 < 200).ConclusionsConsidering that the TST is recommended by the Brazilian health authorities, coverage for taking the test was very low. The most serious implication of this is that LTBI treatment was not carried out for the unidentified TST-positive patients, who may consequently go on to develop TB and eventually die.

show abstract